Syndax Pharmaceuticals (SNDX) Given Somewhat Favorable Media Coverage, Analysis Shows

Syndax Pharmaceuticals (SNDX) Given Somewhat Favorable Media Coverage, Analysis Shows

Media coverage about Syndax Pharmaceuticals (NASDAQ:SNDX) has been trending somewhat positive on Thursday, according to Alpha One Sentiment Analysis. Alpha One, a division of Accern, identifies negative and positive media coverage by analyzing more than twenty million blog and news sources. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Syndax Pharmaceuticals earned a coverage optimism score of 0.16 on Alpha One’s scale. Alpha One also gave press coverage about the company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an impact on the stock’s share price in the near term.

A number of brokerages have issued reports on SNDX. Citigroup Inc set a $24.00 target price on shares of Syndax Pharmaceuticals and gave the company a “buy” rating in a report on Friday, May 19th. Cowen and Company initiated coverage on shares of Syndax Pharmaceuticals in a research report on Friday, March 24th. They set an “outperform” rating for the company. Oppenheimer Holdings Inc. restated a “buy” rating on shares of Syndax Pharmaceuticals in a research report on Wednesday, March 22nd. Zacks Investment Research lowered shares of Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, May 16th. Finally, ValuEngine upgraded shares of Syndax Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, May 18th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $23.75.

Shares of Syndax Pharmaceuticals (SNDX) traded up 4.86% on Thursday, reaching $12.73. 254,204 shares of the company traded hands. The firm’s market capitalization is $232.39 million. The stock has a 50-day moving average price of $10.72 and a 200 day moving average price of $10.21. Syndax Pharmaceuticals has a 1-year low of $6.31 and a 1-year high of $18.03.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings results on Monday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.03. The company had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.31 million. Syndax Pharmaceuticals had a negative net margin of 3,388.98% and a negative return on equity of 306.05%. Analysts anticipate that Syndax Pharmaceuticals will post ($3.69) EPS for the current fiscal year.

In other Syndax Pharmaceuticals news, insider Peter Ordentlich sold 5,000 shares of Syndax Pharmaceuticals stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $15.00, for a total value of $75,000.00. Following the sale, the insider now directly owns 5,000 shares in the company, valued at approximately $75,000. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:SNDX”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment